2. Search Result
Search Result
Results for "

T24

" in MedChemExpress (MCE) Product Catalog:

41

Inhibitors & Agonists

3

Peptides

2

Inhibitory Antibodies

8

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-108719
    Insulin glargine
    1 Publications Verification

    		 Insulin Receptor Akt Metabolic Disease Cancer
    Insulin glargine is a long-acting insulin analog. Insulin glargine has the effect of lowering blood sugar and can be used in the research of diabetes. In addition, high doses of Insulin glargine can promote the proliferation of bladder cancer cells .
    Insulin glargine
  • HY-N2420
    Flavokawain A
    2 Publications Verification

    		 Apoptosis Histone Methyltransferase Cytochrome P450 Caspase Survivin IAP p38 MAPK PI3K NO Synthase COX JNK ERK Akt Inflammation/Immunology Cancer
    Flavokawain A is a chalcone compound and an orally active inhibitor of PRMT5 and cytochrome P450. Flavokawain A has anti-inflammatory, anti-tumor, and immunomodulatory effects. Flavokawain A can inhibit the proliferation of tumor cells and induce apoptosis. Flavokawain A can be used in the research of diseases such as bladder cancer .
    Flavokawain A
  • HY-N1486
    Ursonic acid
    1 Publications Verification

    3-Ketoursolic acid

    		 Apoptosis Endogenous Metabolite NF-κB Inflammation/Immunology Cancer
    Ursolic acid is a naturally occurring triterpenoid that has orally active. Ursolic acid induces the apoptosis of human cancer cells through multiple signaling pathways. Ursolic acid has anti-inflammatory and anticarcinogenic activity .
    Ursonic acid
  • HY-N2877
    Annonacin
    1 Publications Verification

    		 Potassium Channel Sodium Channel Na+/K+ ATPase Calcium Channel Apoptosis Neurological Disease Cancer
    Annonacin is an acetylgenin that is toxic by inhibiting the pathway of the mitochondrial complex. Annonacin increases tau phosphorylation in R406W +/+ mice. Annonacin acts as an inhibitor of the sodium/potassium and sarcoplasmic reticulum (SERCA) ATPase pumps. Annonacin has significant killing effect on ovarian cancer cell, cervical cancer cell, breast cancer cell, bladder cancer cell and skin cancer cell. Annonacin induces apoptosis through Bax and Caspase-3-related pathways .
    Annonacin
  • HY-P99899
    Samrotamab

    PR-1498487

    		 ADC Antibody Cancer
    Samrotamab (PR-1498487) is a humanized IgG1-κ chimeric antibody targeting LRRC15. Samrotamab markedly reduces bladder cancer cells viability and inhibits clonogenic growth, migratory and invasive capabilities. Samrotamab significantly increases LRRC15 mRNA level while suppressing SCG5 mRNA expression. Samrotamab can be used for synthesis of ADC ABBV-085 .
    Samrotamab
  • HY-156418
    KY386

    		DNA/RNA Synthesis Ferroptosis Apoptosis Reactive Oxygen Species (ROS) Cancer
    KY386 is a DHX33 helicase inhibitor with an IC50 of 0.019 μM. KY386 inhibits the cell viability of various cancer cells. KY386 induces ferroptosis in cancer cells, and induces apoptosis in some cancer cell lines. KY386 increases the intracellular levels of ROS, LPO and Fe 2+, and decreases the level of GSH in cancer cells . KY386 inhibits the growth of gastric cancer and colon cancer xenografts in nude mice. KY386 is applicable to the related research on liver cancer, lung cancer, pancreatic cancer, colorectal cancer, gastric cancer, breast cancer, leukemia, renal cancer, prostate cancer, esophageal cancer, cervical cancer, brain cancer (glioblastoma) and melanoma .
    KY386
  • HY-135564A
    RK-682

    		Phosphatase Phospholipase HIV Protease ERK Autophagy Infection Cancer
    RK-682 is the inhibitor for protein tyrosine phosphatase (PTPase), heparanase, phospholipase A2 and HIV-1 protease. RK-682 inhibits the dephosphorylation of CD45 (IC50 is 54 μM) and VHR (IC50 is 2.0 μM), and thereby inhibits the ERK signaling pathway. RK-682 inhibits the cell viability of cancer cell MGH-U3, T24 and UROtsa with IC50s of 78.2, 43.2 and 145 nM, respectively, arrests the cell cycle at G1/S phase, inhibits the cell migration and autophagy in MGH-U3 and T24 .
    RK-682
  • HY-171030
    Pro-GA

    		Reactive Oxygen Species (ROS) Cancer
    Pro-GA is a γ-glutamyl cyclotransferase (GGCT) inhibitor. Pro-GA inhibits the enzymatic activity of GGCT, disrupts glutathione homeostasis, induces the production of mitochondrial ROS, and upregulates the expression of p21, p27 and p16 in cells. Pro-GA inhibits the growth of cancer cells, induces cell cycle arrest and cellular senescence. Pro-GA exerts anti-tumor effects in breast cancer xenograft mouse models. Pro-GA can be used in research related to bladder cancer and breast cancer .
    Pro-GA
  • HY-130723A
    AMPK activator 2 hydrochloride

    		AMPK Cancer
    AMPK activator 2 (compound 7a) hydrochloride, a fluorine-containing proguanil derivative, up-regulates AMPK signal pathway and downregulates mTOR/4EBP1/p70S6K. AMPK activator 2 hydrochloride inhibits proliferation and migration of human cancer cell lines (UMUC3, T24, A549) .
    AMPK activator 2 hydrochloride
  • HY-174086
    PROTAC GPX4 degrader-4

    		Glutathione Peroxidase Ferroptosis ROS Kinase PROTACs Cancer
    PROTAC GPX4 degrader-4 is a GPX4 PROTAC degrader (DC50: 5.32 nM). PROTAC GPX4 degrader-4 inhibits the activity of RT4, T24, and J82 cancer cells (IC50 values are 0.09, 2.97, and 7.58 μM, respectively). PROTAC GPX4 degrader-4 increases lipid ROS levels and induces ferroptosis in T24 and RT4 cells. PROTAC GPX4 degrader-4 has antitumor activity in T24 tumor-bearing BALB/c nude mouse model. PROTAC GPX4 degrader-4 can be used for bladder cancer research. (Pink: target protein ligand (HY-N0193); blue: E3 ligase ligand (HY-1035960); black: linker (HY-W013907); E3 ligase ligand + linker (HY-174087)) .
    PROTAC GPX4 degrader-4
  • HY-177270
    CHNQD-01281

    		EGFR Drug Derivative Cancer
    CHNQD-01281, a derivative of Brefeldin A (HY-16592), is a EGFR modulator. CHNQD-01281 has strong antiproliferative activities against cancer cells (IC50: 0.079 and 0.081 μM for T24 and J82 cells, respectively). CHNQD-01281 regulates both EGFR/PI3K/AKT and EGFR/ERK pathways and mediates the chemotactic effect of chemokines on immune effector cells. CHNQD-01281 remarkably inhibits tumor growth in T24 xenograft mice model and prolongs the survival time in MB49 allogeneic mice model via inducing infiltration of cytotoxic T cells .
    CHNQD-01281
  • HY-146335
    CLK1/4-IN-1

    		CDK Cancer
    CLK1/4-IN-1 (compound 31) is a potent and selective Clk1 and Clk4 inhibitor with an IC50 value of 9.7 nM and 6.6 nM, respectively. CLK1/4-IN-1 has growth inhibitory activities against T24 cancer cells with GI50 of 1.1 μM. CLK1/4-IN-1 can be used for researching anticancer .
    CLK1/4-IN-1
  • HY-146461
    Anticancer agent 58

    		Apoptosis Caspase ROS Kinase Cancer
    Anticancer agent 58 (compound 16) has inhibitory activity against kinds of cancer cell lines, especially in A549 and T24 with IC50s of 0.6 μM and 0.7 μM, respectively. Anticancer agent 58 induces apoptosis by activating caspase 3/8/9 activity, and induces an increase of Ca 2+ and ROS in cancer cells. Anticancer agent 58 significantly decreases mitochondrial membrane potential. Anticancer agent 58 can suppress tumor growth in T24 mouse xenograft model .
    Anticancer agent 58
  • HY-135564
    RK-682 hemicalcium

    		Phosphatase Phospholipase HIV Protease ERK Autophagy Infection Cancer
    RK-682 hemicalcium is the hemicalcium salt form of RK-682 (HY-135564A). RK-682 hemicalcium is the inhibitor for protein tyrosine phosphatase (PTPase), heparanase, phospholipase A2 and HIV-1 protease. RK-682 hemicalcium inhibits the dephosphorylation of CD45 (IC50 is 54 μM) and VHR (IC50 is 2.0 μM), and thereby inhibits the ERK signaling pathway. RK-682 hemicalcium inhibits the cell viability of cancer cell MGH-U3, T24 and UROtsa with IC50s of 78.2, 43.2 and 145 nM, respectively, arrests the cell cycle at G1/S phase, inhibits the cell migration and autophagy in MGH-U3 and T24 [2] .
    RK-682 hemicalcium
  • HY-111193
    Declopramide

    3-Chloroprocainamide

    		 NF-κB Apoptosis Cancer
    Declopramide (3-Chloroprocainamide) is an orally active antitumor agent, which inhibits proliferation of cancer cells HL60 and K562, and inhibits tumor growth of human brain astrocytoma (T24) in mouse model. Declopramide induces apoptosis, inhibits NF-κB through inhibition of IκBα degradation. Declopramide serves also as chemosensitizer in research .
    Declopramide
  • HY-141649
    Anticancer agent 251

    		Apoptosis Autophagy Ferroptosis Cancer
    Anticancer agent 251 (compound 7j) can induce cell death of bladder cancer cell T24 by inducing apoptosis, autophagy or ferroptosis .
    Anticancer agent 251
  • HY-130723
    AMPK activator 2

    		AMPK Cancer
    AMPK activator 2 (compound 7a), a fluorine-containing proguanil derivative, up-regulates AMPK signal pathway and downregulates mTOR/4EBP1/p70S6K. AMPK activator 2 inhibits proliferation and migration of human cancer cell lines (UMUC3, T24, A549) .
    AMPK activator 2
  • HY-149717
    Antitumor agent-122

    		Ferroptosis Apoptosis Autophagy Cancer
    Antitumor agent-122 (Compound 5j) is an antitumor agent with good efficacy, limited toxicity and low resistance. Antitumor agent-122 has antiproliferative activity for MGC-803 cell, HepG2 cell, SKOV3 cell and T24 cell with IC50 values of 5.23 μM, 3.60 μM, 1.43 μM, 3.03 μM, respectively .
    Antitumor agent-122
  • HY-144340
    Antitumor agent-43

    		DNA/RNA Synthesis Apoptosis Cancer
    Antitumor agent-43 (Compound 4B) is a potent antitumor agent, with an IC50of 0.5 µM for (T-24 cell). Antitumor agent-43 (Compound 4B) induces cell cycle arrest at G2/M phase .
    Antitumor agent-43
  • HY-165114
    6-Hydroxyramulosin

    		Endogenous Metabolite Cancer
    6-Hydroxyramulosin is a fungal metabolite with antiancer effects. 6-Hydroxyramulosin shows cytotoxic effects against A549 and T24, showing IC50 values of 14.2 µg/mL and 15.3 µg/mL, respectively .
    6-Hydroxyramulosin
  • HY-161341
    β-Glucuronidase responsive conjugate 1

    		Photosensitizer Cancer
    β-Glucuronidase responsive conjugate 1 (compound 3) is a well-balanced photosensitizer which has photodynamic activity. β-Glucuronidase responsive conjugate 1 inhibits T-24 cell viability and growth with an IC50 of 0.2 μM. β-Glucuronidase responsive conjugate 1 can used to study bladder cancers .
    β-Glucuronidase responsive conjugate 1
  • HY-173280
    Brefeldin A 4-O-nicotinate

    CHNQD-01228

    		 Arf Family GTPase BMX Kinase Cancer
    Brefeldin A 4-O-nicotinate (CHNQD-01228) is a dual inhibitor of Arf1 and BMX proteins. The IC50 value for the proliferation of T24 cells is 0.22 μM. It can also dose-dependently inhibit the migration and colony formation of T24 cells, induce G1 phase arrest and trigger Apoptosis. Brefeldin A 4-O-nicotinate exerts its anti-cancer activity by targeting the BMX protein to inhibit the AKT/p-AKT and STAT3/p-STAT3 signaling pathways, as well as by inhibiting the Arf1 protein to eliminate bladder cancer stem cells and activate anti-tumor immunity. Brefeldin A 4-O-nicotinate can be used in the research related to bladder cancer .
    Brefeldin A 4-O-nicotinate
  • HY-113636
    Kazinol A

    		Apoptosis Autophagy Akt AMPK Cancer
    Kazinol A induces cytotoxic effects in human bladder cancer cells, including the cisplatin-resistant T24R2 .
    Kazinol A
  • HY-N14056
    Chrolactomycin

    		Bacterial Infection Cancer
    Chrolactomycin is found in the strain of Streptomyces sp. 569N-3. The IC50 of Chrolactomycin for ACHN, A431, McF-7 and T24 cells are 1.2 μM, 1.6 μM, 0.69 μM and 0.45 μM, respectively. Chrolactomycin has only anti-Gram-positive bacteria activity with the MIC of 5.2-10.4 μg/mL .
    Chrolactomycin
  • HY-173473
    Anticancer agent 272

    		Reactive Oxygen Species (ROS) Apoptosis Ferroptosis Cancer
    Anticancer agent 272 (Compound 2) is an anticancer agent. Anticancer agent 272 has significant anti-bladder cancer cell (T-24) activity (IC50: 2.81 μM). Anticancer agent 272 consumes glutathione (GSH) through Fenton-like reaction, produces reactive oxygen species (ROS) and hydroxyl radicals (?OH), and induces apoptosis and ferroptosis. Anticancer agent 272 can enhance chemodynamic therapy (CDT) and promote tumor cell death through mitochondrial dysfunction and autophagy. Anticancer agent 272 has potential in the study of bladder cancer .
    Anticancer agent 272
  • HY-149292
    SR-4133

    		Casein Kinase Cancer
    SR-4133 is a potent and highly CK1ε selective inhibitor with an IC50 of 58 nM. SR-4133 binds to the ATP-binding site of CK1ε. SR-4133 displays nanomolar growth inhibition of bladder cancer cells, and inhibits the phosphorylation of 4E-BP1 .
    SR-4133
  • HY-N2420R
    Flavokawain A (Standard)

    		Reference Standards Apoptosis Histone Methyltransferase Cytochrome P450 Caspase Survivin IAP p38 MAPK PI3K NO Synthase COX JNK ERK Akt Inflammation/Immunology Cancer
    Flavokawain A is a chalcone compound and an orally active inhibitor of PRMT5 and cytochrome P450. Flavokawain A has anti-inflammatory, anti-tumor, and immunomodulatory effects. Flavokawain A can inhibit the proliferation of tumor cells and induce apoptosis. Flavokawain A can be used in the research of diseases such as bladder cancer .
    Flavokawain A (Standard)
  • HY-151137
    HSP90/mTOR-IN-1

    		mTOR HSP Apoptosis Autophagy Cancer
    HSP90/mTOR-IN-1 is a potent and orally active Hsp90 and mTOR inhibitor with IC50 values of 69 nM and 29 nM, respectively. HSP90/mTOR-IN-1 suppresses the proliferation of SW780 cells through the over-activation of the PI3K/AKT/mTOR pathway. HSP90/mTOR-IN-1 induces apoptosis and autophagy via selective Hsp90 and mTOR inhibition. HSP90/mTOR-IN-1 also has considerable in vivo anti-tumor activity. HSP90/mTOR-IN-1 can be used for researching bladder cancer .
    HSP90/mTOR-IN-1
  • HY-169406
    α-Glucosidase-IN-76

    		Glycosidase Cancer
    α-Glucosidase-IN-76 (Compound 4r) is an inhibitor for α-glucosidase with an IC50 of 5.44 μM. α-Glucosidase-IN-76 scavenges ABTS+ free radicals with a TEAC value of 0.49. α-Glucosidase-IN-76 inhibits the proliferation of T24 bladder cancer cell with IC50 of 1.74 μM .
    α-Glucosidase-IN-76
  • HY-N15348
    Aphidicolins B32

    		Others Cancer
    Aphidicolins B32 is a diterpenoid compound discovered in the marine fungus Botryotinia fuckeliana, exhibiting cytotoxic activity against human bladder cancer cells. It inhibits the proliferation of T24 cells in the G0/G1 phase, with an IC50 of 27.6 μM. Aphidicolins B32 holds potential for research in the field of cancer therapy .
    Aphidicolins B32
  • HY-179483
    CYP51-IN-31

    		Cytochrome P450 Fungal Infection
    CYP51-IN-31 (compound T24) is a selective CYP51 inhibitor with potent and broad-spectrum antifungal activity, including efficacy against drug-resistant fungal strains. CYP51-IN-31 exhibits fungicidal activity against Candida parapsilosis, anti-biofilm activity, and the ability to inhibit fungal morphological transitions. CYP51-IN-31 can be used for infection research .
    CYP51-IN-31
  • HY-173000
    STAT3-IN-40

    		Apoptosis Ferroptosis STAT Cancer
    STAT3-IN-40 (Compound 8b) is an anti-cancer agent. STAT3-IN-40 can trigger the immune responses of CD4+ and CD8+ T lymphocytes and induce ferroptosis and apoptosis of tumor cells by inhibiting the expression and phosphorylation of STAT3. STAT3-IN-40 can be used in the research of chemoimmunotherapeutic agents for cancer .
    STAT3-IN-40
  • HY-146462
    Anticancer agent 59

    		Apoptosis ROS Kinase Cancer
    Anticancer agent 59 (compound 11) has inhibitory activity against kinds of cancer cell lines, especially in A549 with IC50 of 0.2 μM. Anticancer agent 59 induces apoptosis and an increase of Ca 2+ and ROS in cancer cells. Anticancer agent 59 significantly decreases mitochondrial membrane potential. Anticancer agent 59 can suppress tumor growth in A549 mouse xenograft model .
    Anticancer agent 59
  • HY-N1486R
    Ursonic acid (Standard)

    3-Ketoursolic acid (Standard)

    		 Reference Standards Apoptosis Endogenous Metabolite NF-κB Inflammation/Immunology Cancer
    CSRM617 (Standard) is the analytical standard of CSRM617. This product is intended for research and analytical applications. CSRM617 is a selective small-molecule inhibitor of the transcription factor ONECUT2 (OC2, a master regulator of androgen receptor) with a Kd of 7.43 uM in SPR assays, binding to OC2-HOX domain directly. CSRM617 induces apoptosis by appearance of cleaved Caspase-3 and PARP. CSRM617 is well tolerated in the prostate cancer mouse model
    Ursonic acid (Standard)
  • HY-P3808
    [D-Pro2,D-Trp7,9] Substance P

    		Neurokinin Receptor Inflammation/Immunology
    [D-Pro2,D-Trp7,9] Substance P, a Substance P (HY-P0201) analogue, is a weak agonist and a potent, specific, competitive Substance P antagonist .
    [D-Pro2,D-Trp7,9] Substance P
  • HY-108719R
    Insulin glargine (Standard)

    		Reference Standards Insulin Receptor Akt Metabolic Disease Cancer
    Insulin glargine (Standard) is the analytical standard of Insulin glargine (HY-108719). This product is intended for research and analytical applications. Insulin glargine is a long-acting insulin analog. Insulin glargine has the effect of lowering blood sugar and can be used in the research of diabetes. In addition, high doses of Insulin glargine can promote the proliferation of bladder cancer cells .
    Insulin glargine (Standard)
  • HY-183312
    Antitumor agent-217

    		ATP Synthase Reactive Oxygen Species (ROS) Apoptosis Ferroptosis Cancer
    Antitumor agent-217 is a dual mitochondria-targeted anticancer agent. Antitumor agent-217 exhibits potent and selective antiproliferative activity against bladder cancer cell line J82 (IC50 = 6.3 μM), and inhibits colony formation and migration of J82 cells. Antitumor agent-217 accumulates in mitochondria, alters mitochondrial morphology, reduces ATP production, increases ROS generation and decreases mitochondrial membrane potential. Antitumor agent-217 induces apoptosis (Apoptosis) and ferroptosis (Ferroptosis) in bladder cancer cells. Antitumor agent-217 can be used for the research of bladder cancer .
    Antitumor agent-217
  • HY-183297
    CDK4-IN-5

    		CDK Cancer
    CDK4-IN-5 is a potent, orally active and selective CDK4 inhibitor. CDK4-IN-5 suppresses CDK4 expression and downregulates the CDK4/CyclinD1 complex. CDK4-IN-5 induces G0/G1 phase cell cycle arrest in bladder cancer cells via CyclinD1 expression suppression. CDK4-IN-5 selectively exerts activity against bladder cancer cells. CDK4-IN-5 can be used for the research of bladder cancer .
    CDK4-IN-5
  • HY-182747
    HDAC6-IN-79

    		HDAC Autophagy Apoptosis Cancer
    HDAC6-IN-79 is a HDAC6 inhibitor with an IC50 of 98.40 nM, and it also exhibits inhibitory activity against other HDAC subtypes (HDAC1: 639.0 nM, HDAC2: 798.9 nM, HDAC8: 865.7 nM, HDAC4: 1187 nM). HDAC6-IN-79 induces acetylation of α-tubulin and histone H3, reduces the viability of cancer cells, activates the autophagy pathway and induces apoptosis. HDAC6-IN-79 can be used for research related to urothelial carcinoma (bladder cancer) .
    HDAC6-IN-79
  • HY-181489
    SARS-CoV-2 3CLpro-IN-35

    		SARS-CoV Infection Cancer
    SARS-CoV-2 3CLpro-IN-35 is a SARS-CoV-2 3CLpro inhibitor with an IC50 of 0.15 μM. SARS-CoV-2 3CLpro-IN-35 inhibits the proliferation of bladder cancer cells, exerts anti-SARS-CoV-2 activity, and exhibits low cytotoxicity in fibroblasts. SARS-CoV-2 3CLpro-IN-35 is applicable to research related to SARS-CoV-2 infection and bladder cancer .
    SARS-CoV-2 3CLpro-IN-35
  • HY-181353
    α-Glucosidase-IN-112

    		Glycosidase Metabolic Disease Cancer
    α-Glucosidase-IN-112 is an α-glucosidase inhibitor with an IC50 of 2.03 μM and a Ki of 0.44 μM. α-Glucosidase-IN-112 exerts antioxidant effects by scavenging ABTS + free radicals. α-Glucosidase-IN-112 exerts antiproliferative effects by inhibiting the proliferation of bladder cancer cells. α-Glucosidase-IN-112 can be used in research related to type 2 diabetes and bladder cancer .
    α-Glucosidase-IN-112

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: